Breakthrough status for encorafenib combo for treating colon cancer

New data shows subcutaneous effective as IV for Chron’s treatment
Credit: Sebastian Kaulitzki

Array BioPharma has secured Breakthrough Therapy Designation in the US for encorafenib in combination with binimetinib and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).

BRAFV600E-mutant mCRC patients have a mortality risk more than double that of mCRC patients without the mutation, and currently there are no therapies specifically approved for this high unmet need population.

“We are delighted that the FDA has recognized the potential of this combination for patients with BRAFV600E-mutant metastatic colorectal cancer,” said Victor Sandor, Chief Medical Officer.

“As there are no regimens approved specifically for BRAFV600E-mutant mCRC, this designation provides us with the opportunity to work closely with the FDA to potentially accelerate our effort to bring an important treatment option to these patients in critical need.”